Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 1/20 | 0.45 |
| ▸ | STAT3 | P40763 | 1/20 | 0.38 |
| ▸ | ACLY | P53396 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29756085 | 1.00 | PTPN1 (0.45) | PTPN1STAT3ACLY | |
| SCHEMBL377306 | 1.00 | PTPN1 (0.45) | PTPN1STAT3ACLY | |
| SCHEMBL21757939 | 0.78 | PTPN1 (0.40) | PTPN1STAT3 | |
| SCHEMBL30455949 | 0.78 | PTPN1 (0.40) | PTPN1STAT3 | |
| SCHEMBL158316 | 0.75 | NR1I2 (0.37) | PTPN1 | |
| SCHEMBL29349988 | 0.75 | NR1I2 (0.37) | PTPN1 | |
| SCHEMBL29456643 | 0.75 | NR1I2 (0.37) | PTPN1 | |
| SCHEMBL13767028 | 0.74 | STAT3 (0.38) | PTPN1STAT3 | |
| SCHEMBL19117757 | 0.74 | STAT3 (0.41) | PTPN1STAT3 | |
| SCHEMBL3092052 | 0.74 | STAT3 (0.41) | PTPN1STAT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 137 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4674283-A1 | A COMPOSITION FOR IMPARTING A CURED MEAT APPEARANCE AND/OR FLAVOUR | Kerry Group Services International Limited (IE) | 2026-01-07 | — | — | EP | claimed |
| WO-2025090057-A1 | ENCAPSULATION OF INSECTICIDES INTO BIOPOLYMER CAPSULES | UNM RAINFOREST INNOVATIONS (US) | 2025-05-01 | — | — | WO | claimed |
| US-20240238219-A1 | CURCUMIN AND TURMERONE COMPOSITIONS & METHODS OF USE THEREOF | CAVALERI HEALTH, INC. (CA) | 2024-07-18 | — | — | US | claimed |
| US-20240081341-A1 | ENCAPSULATION OF INSECTICIDES INTO BIOPOLYMER CAPSULES | FUNDACAO OSWALDO CRUZ (BR) | 2024-03-14 | — | — | US | claimed |
| US-20230321177-A1 | POLYPHARMACEUTICAL DRUG COMPOSITIONS AND RELATED METHODS | AVETA BIOMICS, INC. | 2023-10-12 | — | — | US | claimed |
| EP-3773654-B1 | POLYPHARMACEUTICAL DRUG COMPOSITIONS AND RELATED METHODS | AVETA BIOMICS INC (US) | 2023-09-20 | — | — | EP | claimed |
| US-11701402-B2 | Polypharmaceutical drug compositions and related methods | AVETA BIOMICS, INC. (US) | 2023-07-18 | — | — | US | claimed |
| US-20220408729-A1 | COMPOSITIONS CONTAINING METALLIC COMPOUNDS FOR PROLONGED DISINFECTION OF SURFACES AND THEIR USES | NANOMATERIALES QUIMICOS AVANZADOS, S.A. DE C.V. (MX) | 2022-12-29 | — | — | US | claimed |
| WO-2022229784-A1 | MIXTURES OF EMULSIFIED TERPENES HAVING ANTIBACTERIAL AND ANTIFUNGAL ACTIVITY | VILLAGOMEZ DIAZ, Jennifer Paulina (EC) | 2022-11-03 | — | — | WO | claimed |
| US-20220193177-A1 | METHODS AND COMPOSITIONS FOR TREATING DYSBIOSIS OF ORAL MICROBIOME | AVETA BIOMICS, INC. | 2022-06-23 | — | — | US | claimed |
| WO-2013004740-A1 | ANTICONVULSANT ACTIVITY OF TURMERIC OIL AND BISABOLENE SESQUITERPENOIDS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2013-01-10 | — | — | WO | claimed |
| WO-2010062260-A1 | VIRUS AND TARGET CELL INTERACTION INHIBITION | THE THAILAND RESEARCH FUND (TH) | 2010-06-03 | — | — | WO | claimed |
| EP-1453528-B1 | COMPOSITIONS CONTAINING CURCUMA EXTRACTS FOR THE TREATMENT OF NEUROCEREBROVASCULAR DISORDERS | COUNCIL SCIENT IND RES (IN) | 2009-07-22 | — | — | EP | claimed |
| CN-101400359-A | Extracts and methods comprising curcuma species | HERBALSCIENCE SINGAPORE PTE LTD (US) | 2009-04-01 | — | — | CN | claimed |
| EP-2010199-A2 | EXTRACTS AND METHODS COMPRISING CURCUMA SPECIES | Herbalscience Singapore Pte. Ltd. (US) | 2009-01-07 | — | — | EP | claimed |
| US-20080312333-A1 | Agent for Preventing/Ameliorating Life Style-Related Diseases Containing Turmeric Essential Oil Component | KANEKA CORPORATION (JP) | 2008-12-18 | — | — | US | claimed |
| US-20080193573-A1 | Extracts and methods comprising curcuma species | HERBALSCIENCE SINGAPORE PTE. LTD. (SG) | 2008-08-14 | — | — | US | claimed |
| WO-2007109210-A2 | EXTRACTS AND METHODS COMPRISING CURCUMA SPECIES | HERBALSCIENCE SINGAPORE PTE. LTD. (US) | 2007-09-27 | — | — | WO | claimed |
| CN-1956713-A | Agent for preventing/amelioration life style-related diseases containing turmeric essential oil component | KANEGAFUCHI CHEMICAL IND (JP) | 2007-05-02 | — | — | CN | claimed |
| EP-1752144-A1 | AGENT FOR PREVENTING/AMELIORATIG LIFE STYLE-RELAETD DISEASES CONTAINING TURMERIC ESSENTIAL OIL COMPONENT | Kaneka Corporation (JP) | 2007-02-14 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240238219-A1 | CURCUMIN AND TURMERONE COMPOSITIONS & METHODS OF USE THEREOF | NTRK2, MINK1, CAMKK2 | PTPN1 2612/4885STAT3 787/4885ACLY 2774/4885 |
| US-11701402-B2 | Polypharmaceutical drug compositions and related methods | PCBP1, CYP3A5, ABCB1 | PTPN1 3815/4885STAT3 2934/4885ACLY 2233/4885 |
| US-20220193177-A1 | METHODS AND COMPOSITIONS FOR TREATING DYSBIOSIS OF ORAL MICROBIOME | NOP2, LPO, UNG | PTPN1 2991/4885STAT3 2883/4885ACLY 719/4885 |
| US-20080193573-A1 | Extracts and methods comprising curcuma species | APP, BACE1, PSEN1 | PTPN1 4826/4885STAT3 3319/4885ACLY 1631/4885 |
| US-20230321177-A1 | POLYPHARMACEUTICAL DRUG COMPOSITIONS AND RELATED METHODS | PCBP1, CYP3A5, ABCB1 | PTPN1 3815/4885STAT3 2934/4885ACLY 2233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.